Axillary lymph node dissection is not required for breast cancer patients with minimal axillary residual disease after neoadjuvant chemotherapy.
Humans
Breast Neoplasms
/ pathology
Middle Aged
Female
Axilla
Lymph Node Excision
/ methods
Neoplasm, Residual
/ pathology
Neoadjuvant Therapy
/ methods
Adult
Aged
Sentinel Lymph Node Biopsy
/ methods
Follow-Up Studies
Neoplasm Recurrence, Local
/ pathology
Prognosis
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Lymph Nodes
/ pathology
Lymphatic Metastasis
Radiotherapy, Adjuvant
/ methods
Retrospective Studies
Neoplasm Staging
Axillary lymph node dissection
Breast Cancer
Breast surgery
Neoadjuvant chemotherapy
Sentinel lymph node biopsy
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
09
07
2024
accepted:
01
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Sentinel lymph node biopsy (SLNB) is widely used in patients who receive neoadjuvant chemotherapy (NAC). Still, axillary lymph node dissection (ALND) is recommended for patients with any axillary residual disease after NAC. The necessity of ALND in patients with minimal axillary disease is unclear. We aim to investigate regional recurrence rates in patients with limited axillary residual disease after NAC underwent SLNB + image-tailored axillary surgery and adjuvant radiotherapy (RT). Patients with clinical stages were T1-3 and N1 at the time of diagnosis, clinically good or complete axillary response after NAC, and limited axillary residue (≤ 3 pathological lymph nodes) with favorable response to NAC in the final pathological examination were included in the study. All patients underwent SLNB + image-tailored axillary surgery. Peripheral lymphatic radiotherapy was applied, and no further surgery was performed in patients with compatible radiology and pathology results. Our study, which evaluated 139 patients with a median age of 47 years, found that the median number of excised lymph nodes was 4. Notably, 46% of patients had between 1 and 3 lymph nodes excised, while 45% had between 4 and 6. Only 9% of patients had ≥ 7 lymph nodes. 83(60%) of the patients underwent breast-conserving surgery (BCS), and 56(40%) underwent mastectomy. The study's median follow-up period was 44 months. During this duration, one breast recurrence (0.7%), one supraclavicular recurrence (0.7%), and six systemic recurrences (4.3%) were observed. No axillary recurrence occurred within the follow-up period. Patients presenting with pathological-suspicious ≤ 3 lymph nodes on imaging and showing a good response to NAC can be considered suitable candidates for SLNB + image-tailored axillary surgery, followed by adjuvant RT instead of ALND.
Sections du résumé
BACKGROUND
BACKGROUND
Sentinel lymph node biopsy (SLNB) is widely used in patients who receive neoadjuvant chemotherapy (NAC). Still, axillary lymph node dissection (ALND) is recommended for patients with any axillary residual disease after NAC. The necessity of ALND in patients with minimal axillary disease is unclear. We aim to investigate regional recurrence rates in patients with limited axillary residual disease after NAC underwent SLNB + image-tailored axillary surgery and adjuvant radiotherapy (RT).
METHODS
METHODS
Patients with clinical stages were T1-3 and N1 at the time of diagnosis, clinically good or complete axillary response after NAC, and limited axillary residue (≤ 3 pathological lymph nodes) with favorable response to NAC in the final pathological examination were included in the study. All patients underwent SLNB + image-tailored axillary surgery. Peripheral lymphatic radiotherapy was applied, and no further surgery was performed in patients with compatible radiology and pathology results.
RESULTS
RESULTS
Our study, which evaluated 139 patients with a median age of 47 years, found that the median number of excised lymph nodes was 4. Notably, 46% of patients had between 1 and 3 lymph nodes excised, while 45% had between 4 and 6. Only 9% of patients had ≥ 7 lymph nodes. 83(60%) of the patients underwent breast-conserving surgery (BCS), and 56(40%) underwent mastectomy. The study's median follow-up period was 44 months. During this duration, one breast recurrence (0.7%), one supraclavicular recurrence (0.7%), and six systemic recurrences (4.3%) were observed. No axillary recurrence occurred within the follow-up period.
CONCLUSIONS
CONCLUSIONS
Patients presenting with pathological-suspicious ≤ 3 lymph nodes on imaging and showing a good response to NAC can be considered suitable candidates for SLNB + image-tailored axillary surgery, followed by adjuvant RT instead of ALND.
Identifiants
pubmed: 39478502
doi: 10.1186/s12957-024-03547-7
pii: 10.1186/s12957-024-03547-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
286Informations de copyright
© 2024. The Author(s).
Références
Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, Veronesi P, Intra M, Maisonneuve P, Zucca F, Gatti G. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251(4):595–600.
doi: 10.1097/SLA.0b013e3181c0e92a
pubmed: 20195151
Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75.
doi: 10.1056/NEJMoa020128
pubmed: 12192016
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol. 2010;11(10):927–33.
doi: 10.1016/S1470-2045(10)70207-2
pubmed: 20863759
pmcid: 3041644
Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599–609.
doi: 10.1093/jnci/djj158
pubmed: 16670385
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918–26.
doi: 10.1001/jama.2017.11470
pubmed: 28898379
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomized, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.
doi: 10.1016/S1470-2045(14)70460-7
pubmed: 25439688
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP. Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(3):310–20.
doi: 10.6004/jnccn.2018.0012
Al-Hilli Z, Hoskin TL, Day CN, Habermann EB, Boughey JC. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol. 2018;25:482–93.
doi: 10.1245/s10434-017-6263-y
pubmed: 29181679
Nguyen TT, Hoskin TL, Day CN, Degnim AC, Jakub JW, Hieken TJ, Boughey JC. Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25:2596–602.
doi: 10.1245/s10434-018-6637-9
pubmed: 29978369
Dwyer, Mary. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) Breast Cancer NCCN.org NCCN Guidelines for Patients ® available at http://www.nccn.org/patients . 2023; Available from: https://www.nccn .
Panda SK, Goel A, Nayak V, Shaik Basha S, Pande PK, Kumar K. Can preoperative ultrasonography and MRI replace sentinel lymph node biopsy in management of axilla in early breast cancer—a prospective study from a tertiary cancer center. Indian J Surg Oncol. 2019;10(3):483–8.
doi: 10.1007/s13193-019-00924-7
pubmed: 31496596
Abe H, Schacht D, Kulkarni K, Shimauchi A, Yamaguchi K, Sennett CA, Jiang Y. Accuracy of axillary lymph node staging in breast cancer patients: an observer-performance study comparison of MRI and ultrasound. Acad Radiol. 2013;20(11):1399–404.
doi: 10.1016/j.acra.2013.08.003
pubmed: 24119352
Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton T, Hunt KK. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260(4):608.
doi: 10.1097/SLA.0000000000000924
pubmed: 25203877
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072.
doi: 10.1200/JCO.2015.64.0094
pubmed: 26811528
Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Feliberti EC, Hunt KK. Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0–T4, N1–2) who receive neoadjuvant chemotherapy–results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802.
doi: 10.1097/SLA.0000000000001375
pubmed: 26649589
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.
doi: 10.1001/jama.2013.278932
pubmed: 24101169
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.
doi: 10.1016/S1470-2045(13)70166-9
pubmed: 23683750
Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp SE. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–64.
doi: 10.1200/JCO.2014.55.7827
pubmed: 25452445
Yan M, Abdi MA, Falkson C. Axillary management in breast cancer patients: a comprehensive review of the key trials. Clin Breast Cancer. 2018;18(6):e1251–9.
doi: 10.1016/j.clbc.2018.08.002
pubmed: 30262257
Galimberti V, Fontana SK, Vicini E, Morigi C, Sargenti M, Corso G, Magnoni F, Intra M, Veronesi P. This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients. Breast. 2023;1(67):21–5.
doi: 10.1016/j.breast.2022.12.010
Wong SM, Basik M, Florianova L, Margolese R, Dumitra S, Muanza T, Carbonneau A, Ferrario C, Boileau JF. Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2021;28:2621–9.
doi: 10.1245/s10434-020-09211-0
pubmed: 33095362
Barrio AV, Montagna G, Mamtani A, Sevilimedu V, Edelweiss M, Capko D, Cody HS, El-Tamer M, Gemignani ML, Heerdt A, Kirstein L. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy—a rare event. JAMA Oncol. 2021;7(12):1851–5.
doi: 10.1001/jamaoncol.2021.4394
pubmed: 34617979
Bartels, S. A. L., Donker, M., Poncet, C., Sauvé, N., Straver, M. E., van de Velde, C. J. H., Mansel, R. E., Blanken, C., Orzalesi, L., Klinkenbijl, J. H. G., van der Mijle, H. C. J., Nieuwenhuijzen, G. A. P., Veltkamp, S. C., van Dalen, T., Marinelli, A., Rijna, H., Snoj, M., Bundred, N. J., Merkus, J. W. S., Belkacemi, Y., … Rutgers, E. J. T. (2023). Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981–22023 AMAROS Trial. J Clin Oncol. 2023; 41(12), 2159–2165. https://doi.org/10.1200/JCO.22.01565
Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Paik S, Gupta N, Li XA, DiCostanzo DJ, Costantino JP, Curran Jr WJ, Wolmark N. NRG Oncology/NSABP B-51/RTOG 1304: A phase III clinical trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypN0 after neoadjuvant chemotherapy (NC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res. 2016;76(4 Suppl):Abstract nr OT2-02-02.
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy | ClinicalTrials.gov. Available from: https://clinicaltrials.gov/study/NCT01901094 .
Mailhot Vega R, Deladisma AM, Mobley EM, Wang S, Morris CG, Oladeru OT, Brooks E, Gharia BM, Spiguel LR, MacDonald SM, et al. Axillary Surgery Efficacy for Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy on NSABP B40 and B41. J Clin Oncol. 2023;41:524. https://doi.org/10.1200/JCO.2023.41.16_suppl.524 .
van Loevezijn AA, van der Noordaa ME, Stokkel MP, van Werkhoven ED, Groen EJ, Loo CE, Elkhuizen PH, Sonke GS, Russell NS, van Duijnhoven FH, Vrancken Peeters MJ. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol. Breast Cancer Res Treat. 2022;193(1):37–48.
doi: 10.1007/s10549-022-06545-z
pubmed: 35239072
Almahariq MF, Levitin R, Quinn TJ, Chen PY, Dekhne N, Kiran S, Desai A, Benitez P, Jawad MS, Gustafson GS, Dilworth JT. Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy. Ann Surg Oncol. 2021;28:930–40.
doi: 10.1245/s10434-020-08928-2
pubmed: 32712895
Cabıoğlu N, Karanlık H, Yıldırım N, Müslümanoğlu M, Karadeniz GÇ, Can DT, Tükenmez M, Ersoy YE, Uras C, Zengel B, Emiroğlu S. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study. Eur J Surg Oncol. 2021;47(10):2506–14.
doi: 10.1016/j.ejso.2021.06.024
pubmed: 34217580
Kantor O, Wakeman M, Weiss A, Wong S, Laws A, Grossmith S, Mittendorf EA, King TA. Axillary management after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. Ann Surg Oncol. 2021;28:1358–67.
doi: 10.1245/s10434-020-09073-6
pubmed: 32869154
Ahmed M, Jozsa F, Baker R, Rubio IT, Benson J, Douek M. Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients. Breast Cancer Res Treat. 2017;166(2):329–36. https://doi.org/10.1007/s10549-017-4405-3 . Epub 2017 Jul 28. Erratum in: Breast Cancer Res Treat. 2017;166(2):337. PMID: 28755147; PMCID: PMC5668351.
doi: 10.1007/s10549-017-4405-3
pubmed: 28755147
pmcid: 5668351
Kim R, Chang JM, Lee HB, Lee SH, Kim SY, Kim ES, Cho N, Moon WK. Predicting axillary response to neoadjuvant chemotherapy: breast MRI and US in patients with node-positive breast cancer. Radiology. 2019;293(1):49–57. https://doi.org/10.1148/radiol.2019190014 . Epub 2019 Aug 13 PMID: 31407967.
doi: 10.1148/radiol.2019190014
pubmed: 31407967